Although MEK inhibition was reported to enhance BCL-2/xL inhibitors cell death induction in BCP-ALL by Korfi and colleagues, as we also confirmed, as far as we know this is the first time that it is shown that trametinib strongly synergizes with MCL-1 inhibition in this disease. Here, MAP2K7 is linked to acute lymphoblastic leukemia.